163 related articles for article (PubMed ID: 34145771)
1. Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer.
Yoon HG; Oh D; Noh JM; Cho WK; Sun JM; Kim HK; Zo JI; Shim YM; Kim K
J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1144-1152. PubMed ID: 34145771
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer.
Yoon HG; Oh D; Ahn YC; Noh JM; Pyo H; Cho WK; Song YM; Park M; Hwang NY; Sun JM; Kim HK; Zo JI; Shim YM
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290037
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of an Interactive Health Coaching Mobile App to Prevent Malnutrition and Muscle Loss in Esophageal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy: Prospective Pilot Study.
Yang K; Oh D; Noh JM; Yoon HG; Sun JM; Kim HK; Zo JI; Shim YM; Ko H; Lee J; Kim Y
J Med Internet Res; 2021 Aug; 23(8):e28695. PubMed ID: 34448714
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of muscle mass loss in elderly patients with oesophageal cancer receiving neoadjuvant chemoradiation therapy.
Jang JY; Oh D; Noh JM; Sun JM; Kim HK; Shim YM
J Cachexia Sarcopenia Muscle; 2024 Apr; ():. PubMed ID: 38613258
[TBL] [Abstract][Full Text] [Related]
5. Explainable machine learning model for predicting skeletal muscle loss during surgery and adjuvant chemotherapy in ovarian cancer.
Hsu WH; Ko AT; Weng CS; Chang CL; Jan YT; Lin JB; Chien HJ; Lin WC; Sun FJ; Wu KP; Lee J
J Cachexia Sarcopenia Muscle; 2023 Oct; 14(5):2044-2053. PubMed ID: 37435785
[TBL] [Abstract][Full Text] [Related]
6. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of sarcopenia in patients treated by Radiochemotherapy for locally advanced oesophageal cancer.
Mallet R; Modzelewski R; Lequesne J; Mihailescu S; Decazes P; Auvray H; Benyoucef A; Di Fiore F; Vera P; Dubray B; Thureau S
Radiat Oncol; 2020 May; 15(1):116. PubMed ID: 32443967
[TBL] [Abstract][Full Text] [Related]
8. Muscle wasting and survival following pre-operative chemoradiotherapy for locally advanced rectal carcinoma.
Levolger S; van Vledder MG; Alberda WJ; Verhoef C; de Bruin RWF; IJzermans JNM; Burger JW
Clin Nutr; 2018 Oct; 37(5):1728-1735. PubMed ID: 28756039
[TBL] [Abstract][Full Text] [Related]
9. Does the computed tomography perfusion imaging improve the diagnostic accuracy in the response evaluation of esophageal carcinoma to the neoadjuvant chemoradiotherapy? Preliminary study.
Djuric-Stefanovic A; Saranovic D; Micev M; Stankovic V; Plesinac-Karapandzic V; Pesko P; Stojakov D; Sabljak P; Bjelovic M
J BUON; 2014; 19(1):237-44. PubMed ID: 24659670
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?
Saeki H; Nakashima Y; Kudou K; Sasaki S; Jogo T; Hirose K; Edahiro K; Korehisa S; Taniguchi D; Nakanishi R; Kubo N; Ando K; Kabashima A; Oki E; Maehara Y
World J Surg; 2018 Sep; 42(9):2894-2901. PubMed ID: 29488065
[TBL] [Abstract][Full Text] [Related]
11. Low muscle mass measured at T12 is a prognostic biomarker in unresectable oesophageal cancers receiving chemoradiotherapy.
McSweeney DM; Raby S; Radhakrishna G; Weaver J; Green A; Bromiley PA; van Herk M; McWilliam A
Radiother Oncol; 2023 Sep; 186():109764. PubMed ID: 37385375
[TBL] [Abstract][Full Text] [Related]
12. Decreases in the Psoas Muscle Index Correlate More Strongly with Survival than Other Prognostic Markers in Esophageal Cancer After Neoadjuvant Chemoradiotherapy Plus Esophagectomy.
Kawakita Y; Motoyama S; Sato Y; Wakita A; Nagaki Y; Imai K; Minamiya Y
World J Surg; 2020 May; 44(5):1559-1568. PubMed ID: 31907570
[TBL] [Abstract][Full Text] [Related]
13. The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy.
Nakajo M; Kitajima K; Kaida H; Morita T; Minamimoto R; Ishibashi M; Yoshiura T
Clin Radiol; 2020 Jan; 75(1):79.e9-79.e18. PubMed ID: 31662200
[TBL] [Abstract][Full Text] [Related]
14. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
[TBL] [Abstract][Full Text] [Related]
15. Skeletal muscle gauge prediction by a machine learning model in patients with colorectal cancer.
Lim JY; Kim YM; Lee HS; Kang J
Nutrition; 2023 Nov; 115():112146. PubMed ID: 37531791
[TBL] [Abstract][Full Text] [Related]
16. [Effect of Nutrition Intervention on Skeletal Muscle during Concurrent Chemoradiotherapy for Esophageal Cancer].
Ren P; Yang Q
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Oct; 42(5):610-618. PubMed ID: 33131515
[TBL] [Abstract][Full Text] [Related]
17. Machine learning to predict curative multidisciplinary team treatment decisions in oesophageal cancer.
Thavanesan N; Bodala I; Walters Z; Ramchurn S; Underwood TJ; Vigneswaran G
Eur J Surg Oncol; 2023 Nov; 49(11):106986. PubMed ID: 37463827
[TBL] [Abstract][Full Text] [Related]
18. Skeletal muscle loss is an independent negative prognostic factor in patients with advanced lower rectal cancer treated with neoadjuvant chemoradiotherapy.
Takeda Y; Akiyoshi T; Matsueda K; Fukuoka H; Ogura A; Miki H; Hiyoshi Y; Nagasaki T; Konishi T; Fujimoto Y; Fukunaga Y; Ueno M
PLoS One; 2018; 13(4):e0195406. PubMed ID: 29630652
[TBL] [Abstract][Full Text] [Related]
19. Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.
Lee J; Chang CL; Lin JB; Wu MH; Sun FJ; Jan YT; Hsu SM; Chen YJ
Clin Cancer Res; 2018 Oct; 24(20):5028-5036. PubMed ID: 29959140
[No Abstract] [Full Text] [Related]
20. The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study.
Akita H; Takahashi H; Asukai K; Tomokuni A; Wada H; Marukawa S; Yamasaki T; Yanagimoto Y; Takahashi Y; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Ochi A; Kagawa A; Soh Y; Taniguchi Y; Ohue M; Yano M; Sakon M
Clin Nutr ESPEN; 2019 Oct; 33():148-153. PubMed ID: 31451252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
